In silico analysis of flavonoid glycosides and its aglycones as reverse transcriptase inhibitor

Stefandi J. Wijaya, Arry Yanuar, Rosita Handayani, Rezi Riadhi Syahdi

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background: HIV continues to be a major global public health issue, having claimed more than 35 million lives so far. In 2016, 1 million people died from HIV-related causes globally. HIV-1 reverse transcriptase is one of HIV's vital enzymes for virus reproduction. If the enzyme is inhibited, the virus multiplication could be significantly decreased. There are currently many treatments for HIV, but more effective treatment is always needed because of the possibility of drug resistance and side effects for long-term use. Based on the previous study, there are some natural compounds with high affinity to the HIV-1 reverse transcriptase enzyme. Some of these compounds are flavonoid glycosides. Aims and Method: This study was aimed to learn more about in silico HIV-1 reverse transcriptase inhibitory activities of flavonoid glycosides using docking method. Results: The results showed that the most recommended flavonoid glycosides are those with the lowest binding energy, which were kaempferol-3-O-rhamnoside, myricetin-3-O-rhamnoside and quercetin-3-O-rhamnoside. This was due to the interactions of all three flavonoid rings and sugar moiety with key amino acid residues, which were Leu100, Lys101, Glu138, Tyr181, His235 and Tyr318. Conclusion: Flavonoid glycosides with rhamnose as glycone showed lower binding energy on HIV-1 reverse transcriptase.

Original languageEnglish
Pages (from-to)1252-1255
Number of pages4
JournalPharmacognosy Journal
Issue number6
Publication statusPublished - 2019
Externally publishedYes


  • Flavonoid
  • Glycosides
  • HIV
  • Molecular docking
  • Reverse transcriptase


Dive into the research topics of 'In silico analysis of flavonoid glycosides and its aglycones as reverse transcriptase inhibitor'. Together they form a unique fingerprint.

Cite this